Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg-IL PSO (Italian Landscape Psoriasis).

IF 3.5 3区医学 Q1 DERMATOLOGY

Dermatology and Therapy Pub Date : 2025-06-01 Epub Date: 2025-04-23 DOI:10.1007/s13555-025-01416-z

Mario Valenti, Luciano Ibba, Sara Di Giulio, Luigi Gargiulo, Piergiorgio Malagoli, Anna Balato, Federico Bardazzi, Francesco Loconsole, Martina Burlando, Anna E Cagni, Norma Cameli, Carlo G Carrera, Andrea Carugno, Aldo Cuccia, Paolo Dapavo, Eugenia V Di Brizzi, Valentina Dini, Maria C Fargnoli, Francesca M Gaiani, Claudio Guarneri, Claudia Lasagni, Gaetano Licata, Angelo V Marzano, Matteo Megna, Santo R Mercuri, Alessandra Michelucci, Maria L Musumeci, Diego Orsini, Romina Ortega, Luca Potestio, Luca Rapparini, Simone Ribero, Francesca Satolli, Davide Strippoli, Emanuele Trovato, Marina Venturini, Leonardo Zichichi, Pina Brianti, Antonio Costanzo, Alessandra Narcisi

{"title":"Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg-IL PSO (Italian Landscape Psoriasis).","authors":"Mario Valenti, Luciano Ibba, Sara Di Giulio, Luigi Gargiulo, Piergiorgio Malagoli, Anna Balato, Federico Bardazzi, Francesco Loconsole, Martina Burlando, Anna E Cagni, Norma Cameli, Carlo G Carrera, Andrea Carugno, Aldo Cuccia, Paolo Dapavo, Eugenia V Di Brizzi, Valentina Dini, Maria C Fargnoli, Francesca M Gaiani, Claudio Guarneri, Claudia Lasagni, Gaetano Licata, Angelo V Marzano, Matteo Megna, Santo R Mercuri, Alessandra Michelucci, Maria L Musumeci, Diego Orsini, Romina Ortega, Luca Potestio, Luca Rapparini, Simone Ribero, Francesca Satolli, Davide Strippoli, Emanuele Trovato, Marina Venturini, Leonardo Zichichi, Pina Brianti, Antonio Costanzo, Alessandra Narcisi","doi":"10.1007/s13555-025-01416-z","DOIUrl":null,"url":null,"abstract":"Introduction: Tildrakizumab is a monoclonal antibody targeting interleukin (IL)-23 approved for the treatment of moderate-to-severe plaque psoriasis across two different dosages (100 mg and 200 mg). The higher dosage is recommended for patients with a body weight ≥ 90 kg or a high disease burden (Psoriasis Area and Severity Index [PASI] ≥ 16 or the involvement of difficult-to-treat areas). We conducted a 52-week multicenter retrospective study to compare the effectiveness and safety of both dosages and assess their impact on specific patient subgroups.Methods: We enrolled a total of 540 patients with high disease burden or body weight ≥ 90 kg; 177 and 363 were treated with tildrakizumab 200 mg and 100 mg, respectively. The effectiveness was evaluated in terms of PASI 90, PASI 100, and PASI ≤ 2 at weeks 16, 28, and 52. We also performed subanalyses according to the body weight (≥ 90 kg), PASI ≥ 16, prior biologic exposure, involvement of difficult-to-treat areas, and the presence of at least one cardiometabolic comorbidity.Results: After 16 weeks of treatment, a higher proportion of patients in the 200-mg group achieved PASI 90 and PASI 100 compared to those in the 100-mg group (43.5% vs. 34.3% and 36.4% vs. 24.2%, respectively). These results were sustained at 1 year, with PASI 90 and PASI 100 reached by 68.6% and 52.9% of patients in the 200-mg group, respectively, versus 57.3% and 35% in the 100-mg group. All subgroup analyses consistently indicated a trend toward greater effectiveness with tildrakizumab 200 mg, particularly in terms of PASI 90 and PASI 100 achievement at weeks 16 and 52. No differences in the safety profile were observed throughout the study period.Conclusion: Our findings confirm the superior effectiveness of tildrakizumab 200 mg over 100 mg in specific subgroups of patients with a comparable safety profile across the study period.","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"1427-1440"},"PeriodicalIF":3.5000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12092844/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-025-01416-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/23 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Tildrakizumab is a monoclonal antibody targeting interleukin (IL)-23 approved for the treatment of moderate-to-severe plaque psoriasis across two different dosages (100 mg and 200 mg). The higher dosage is recommended for patients with a body weight ≥ 90 kg or a high disease burden (Psoriasis Area and Severity Index [PASI] ≥ 16 or the involvement of difficult-to-treat areas). We conducted a 52-week multicenter retrospective study to compare the effectiveness and safety of both dosages and assess their impact on specific patient subgroups.

Methods: We enrolled a total of 540 patients with high disease burden or body weight ≥ 90 kg; 177 and 363 were treated with tildrakizumab 200 mg and 100 mg, respectively. The effectiveness was evaluated in terms of PASI 90, PASI 100, and PASI ≤ 2 at weeks 16, 28, and 52. We also performed subanalyses according to the body weight (≥ 90 kg), PASI ≥ 16, prior biologic exposure, involvement of difficult-to-treat areas, and the presence of at least one cardiometabolic comorbidity.

Results: After 16 weeks of treatment, a higher proportion of patients in the 200-mg group achieved PASI 90 and PASI 100 compared to those in the 100-mg group (43.5% vs. 34.3% and 36.4% vs. 24.2%, respectively). These results were sustained at 1 year, with PASI 90 and PASI 100 reached by 68.6% and 52.9% of patients in the 200-mg group, respectively, versus 57.3% and 35% in the 100-mg group. All subgroup analyses consistently indicated a trend toward greater effectiveness with tildrakizumab 200 mg, particularly in terms of PASI 90 and PASI 100 achievement at weeks 16 and 52. No differences in the safety profile were observed throughout the study period.

Conclusion: Our findings confirm the superior effectiveness of tildrakizumab 200 mg over 100 mg in specific subgroups of patients with a comparable safety profile across the study period.

查看原文本刊更多论文

优化Tildrakizumab在银屑病中的剂量：一项为期52周的多中心回顾性研究，比较100mg和200mg - il PSO（意大利景观银屑病）。

Tildrakizumab是一种靶向白介素(IL)-23的单克隆抗体，被批准用于两种不同剂量（100mg和200mg）治疗中重度斑块性银屑病。对于体重≥90 kg或疾病负担高（银屑病面积和严重程度指数[PASI]≥16或涉及难以治疗的区域）的患者，建议使用更高的剂量。我们进行了一项为期52周的多中心回顾性研究，比较两种剂量的有效性和安全性，并评估它们对特定患者亚组的影响。方法：我们共入组540例高疾病负担或体重≥90 kg的患者；177例和363例患者分别接受tildrakizumab 200 mg和100 mg治疗。在第16周、28周和52周时，以PASI 90、PASI 100和PASI≤2来评估有效性。我们还根据体重（≥90 kg）、PASI≥16、既往生物暴露、涉及难以治疗的区域以及至少存在一种心脏代谢合并症进行了亚组分析。结果：治疗16周后，与100 mg组相比，200 mg组患者达到PASI 90和PASI 100的比例更高（分别为43.5%对34.3%和36.4%对24.2%）。这些结果持续了1年，200 mg组分别有68.6%和52.9%的患者达到PASI 90和PASI 100，而100 mg组分别为57.3%和35%。所有亚组分析一致表明tildrakizumab 200mg有更大疗效的趋势，特别是在第16周和第52周PASI 90和PASI 100的实现方面。在整个研究期间，没有观察到安全性方面的差异。结论：我们的研究结果证实，在整个研究期间，tildrakizumab 200 mg比100 mg在特定亚组患者中具有更高的有效性，并且具有相当的安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatology and Therapy Medicine-Dermatology

CiteScore

6.00

自引率

8.80%

发文量

187

审稿时长

6 weeks

期刊介绍： Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged. Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.